Dave Ricks

Exciting news from the hashtag#JPMorganHealthcare Conference: Lilly and NVIDIA are joining forces to build a first-of-its-kind AI co-innovation lab—one that holds the potential to reinvent drug dis...

Many chronic conditions are associated with obesity, yet care for them is often managed separately. As our understanding of incretin medicines has evolved, we’re studying their potential in people ...

With FDA submission of our oral GLP-1 for the treatment of obesity, we’re closer than ever to providing this potential medicine to patients on a broad scale—with a decision expected in the first ha...

Wishing you good health, renewed hope and time with those who matter most—this holiday season and in the year ahead. hashtag#WeAreLilly

Alzheimer’s brings days of hope and days of hardship—and families feel every moment. We honor those experiences and the courage and care behind them, as we work toward a future where this disease i...

With this U.S. FDA approval, people facing advanced or metastatic breast cancer with an ESR1 mutation now have access to a new once-daily oral therapy. Thank you to the scientists, clinicians, Lill...

Making life better means serving our communities. Each fall, Lilly teams around the world invest their time and talent to strengthen the places we live and work. I’m grateful to all of my colleague...

Behind our historic commitment to U.S. manufacturing is a simple goal: improving lives and creating opportunity. From patients who need breakthrough medicines to the thousands of skilled workers wh...

Today we’re celebrating another major milestone: the fourth successful Phase 3 trial of our investigational once-daily GLP-1 pill—this time in a head-to-head study against an approved type 2 diabet...

Our historic $50 billion investment in U.S. manufacturing is moving forward—fast. Today, I joined Virginia Gov. Glenn Youngkin and state and local leaders to share plans for our newest advanced ma...